CID2121

Although patients with autosomal dominant polycystic kidney disease (ADPKD) have a higher incidence of intracranial aneurysms than found in the healthy population, research concerning the factors related to the risk of...

Evidence indicates that patients with ADPKD frequently have low levels of urinary citrate. With the suggestion by experts in the field that urinary citrate may be a marker of covert metabolic acidosis in chronic kidney disease,...

Prior research suggests that endothelial dysfunction (ED) is common and occurs much earlier than kidney function impairment in patients with ADPKD. However, data are lacking on the impact of smoking on ED in this patient...

To test the hypothesis that overweight and obesity are independently associated with greater self-reported back, abdominal, and radicular pain at baseline among adults with early- or late-stage ADPKD, and that weight loss is...

With limited real-world data on the safety and efficacy of tolvaptan since its approval to treat ADPKD in 2014, investigators conducted post-marketing surveillance to evaluate the long-term safety and efficacy of the agent in...

Initiating or maintaining tolvaptan therapy significantly delayed estimated glomerular filtration rate (eGFR) decline in patients with baseline eGFR of 15-24 and 25-29 ml/min per 1.73 m2, according to a study published in Kidney...

Autosomal dominant polycystic kidney disease (ADPKD), the most frequent hereditary renal disease that accounts for approximately 6% to 10% of patients initiating renal replacement therapies worldwide, is not usually associated...

Based on prior observations, researchers evaluated the associations of overweight and obesity with rapid progression of ADPKD in participants of the TEMPO 3:4 trial. While doing so, they also assess whether tolvaptan’s efficacy...